Late-Breaking Data on Bladder Cancer Treatments...

By HEOR Staff Writer

February 13, 2026

Breakthroughs in Bladder Cancer Treatments at ASCO GU Merck unveiled promising bladder cancer treatments at the 2026 ASCO Genitourinary (GU) Cancers Symposium, showcasing data fr...
Robotic Surgery Portugal: A Landmark Achievement at ULS Viseu Dão-Lafões
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...
South Africa Health Reform: Navigating Innovations and Challenges for 2026
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
Tislelizumab NSCLC Inclusion Recommended for Dutch Health Package
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...
Ozempic Public Funding Approval in Portugal: Key Insights and Implications
Surge in Obesity Intervention Costs in the Netherlands
HPV Vaccination Benefits Portugal: A Cost-Benefit Analysis of Expansion Effects
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk
CHMP January 2026 Approvals: Expanding Access to Innovative Therapies